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Purpose: Adequate control of breakthrough pain is essential for patients with cancer. Managing breakthrough 
pain mainly depends on understanding the concept of breakthrough pain and the proper usage of rescue medication 
by physicians. This study aims to assess the attitudes and practice patterns of palliative physicians in managing 
breakthrough pain for patients in Korea. Methods: This study was based on data from the 2014 breakthrough 
cancer pain survey conducted by the Korean Society for Hospice and Palliative Care. One hundred physicians 
participated in the online survey. Among total 33 self-reported questionnaires, twelve items were selected in this 
analysis. Results: Rapid onset of action is the main influencing factor in selecting rescue opioids. Oral oxycodone 
(65%) and parenteral morphine (27%) are commonly used. A few physicians (3%) prefer to use transmucosal 
fentanyl. The percentage of physicians prescribing oral oxycodone due to its rapid onset of action is just 21.5%, 
whereas the percentage of physicians using parenteral morphine is 81.5%. Two thirds of respondents (66%) 
answered that breakthrough pain is not well controlled with rescue medications. Conclusion: There is a gap 
between the needs of physicians in terms of the perceived difficulties of managing breakthrough cancer pain and 
their practice patterns selecting rescue medications.
Key Words: Breakthrough pain, Palliative care, Opioid analgesics
INTRODUCTION
Breakthrough cancer pain (BTcP) has been defined as “a 
transient exacerbation of pain that occurs either spontaneously 
or in relation to a specific and predictable or unpredictable 
trigger, despite relatively stable and adequately controlled 
background pain” (1). The prevalence of BTcP varies with 
clinical settings and definitions of BTcP, ranging from 39.9% 
in outpatient clinics to 80.5% in hospice settings (2). The 
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occurrence of breakthrough pain has been reported to interfere 
with daily living, to decrease personal relationships and to 
increase psychological distress, thereby resulting in a poor 
quality of life among cancer patients (3). In addition, cancer 
patients with BTcP are known to require higher costs 
($12,000/year) for hospitalization, emergency department visits, 
and physician office visits than non-BTcP patients ($2,400/year) 
(4).
Despite ongoing improvement of guidelines for pain control 
in cancer patients and the development of effective analgesics, 
BTcP is still considered difficult to manage (5). There are a 
number of barriers against properly managing BTcP. A 
growing body of literature has documented that a fear of 
opioid addiction and tolerance among patients, inadequate 
knowledge and assessment of pain by physicians, and negative 
public attitudes may be barriers to the proper management of 
cancer pain (6,7). Among many treatment modalities, in-
cluding correction of the underlying cause, avoiding pre-
cipitating factors, usage of rescue medication, and non- 
pharmacologic interventions, appropriate usage of rescue medi-
cation is most important (8). Traditionally, oral immediate- 
release opioids such as morphine and other relevant opioid 
analgesics such as oxycodone and hydromorphone have been 
prescribed as rescue medications (9). Some researchers have 
demonstrated, however, that traditional rescue medications 
may not match the temporal characteristics of BTcP (10,11). 
Most episodes of BTcP are characterized by patients reaching 
peak pain intensity within 10 minutes, followed by the 
disappearance of untreated pain within 60 minutes (12). 
Inconsistent with this presentation, almost all immediate- 
release preparations are known in pharmacokinetic studies to 
have delayed onset for producing peak analgesia (＞one hour) 
and long durations of efficacy (3∼6 hours) (13). Therefore, a 
mismatch between temporal characteristics of BTcP and the 
mechanisms of rescue medications may result in suboptimal 
pain management and undesirable adverse effects for patients, 
such as sedation, confusion, and fatigue (14). Recent research 
in other countries has shown that many physicians still use 
conventional rescue medications despite the availability of 
more appropriate opioids (15,16). However, there is little data 
regarding the management of BTcP among Korean physicians. 
The aim of this study is to assess the practice patterns of 
hospice-palliative physicians concerning BTcP and its treatment, 
especially in terms of drugs of choice, the reasoning for these 
preferences, and physician perceptions of what is needed to 
best manage breakthrough cancer pain when it comes to 
rescue medications.
METHODS
1. Study design, participants and procedures
The 2014 breakthrough cancer pain survey conducted by 
the Korean Society for Hospice and Palliative Care (KSHPC) 
was analyzed. This survey was conducted in order to under-
stand physician perceptions about breakthrough cancer pain 
and the pain management practice patterns of physicians. 
Prior to the study, KSHPC recruited a working group. Nine 
members comprised this group, including four family physi-
cians, three medical oncologists, one radiation oncologist, and 
one medical statistician. Among members of the KSHPC, 
medical specialists with regular membership and who are 
managing cancer pain with opioid analgesics in over 10 cases 
per month were eligible for participation. The KSHPC sent 
emails with the address of the online survey to a total of 382 
members, encouraging participation from September to December 
of 2014, until a total of 100 members completed and 
submitted the survey. After completion of the questionnaire, 
participants received a reward for their participation. This 
study was approved by the Institutional Review Board of the 
Yonsei University College of Medicine in Seoul, Korea (IRB 
no. 4-2015-0346). Because this study analyzed existing survey 
data, the exemption of the informed consent requirement was 
determined by the IRB committee.
2. Questionnaire
The questionnaire was specifically developed for the aims of 
the survey by the working group of the KSHPC in accor-
dance with clinical experience and a review of existing 
literature. After several face-to-face meetings and contact via 
email, 33 questions, including seven items addressing back-
ground characteristics such as physician’s age, sex, years of 
practice, and workplace, were selected for inclusion in the final 
survey questionnaire. The instrument also contained questions 
on knowledge of cancer management, barriers to managing 
cancer pain, capacity for pain assessment (including severity, 
frequency and duration of pain), physician level of education 
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Table 1. Characteristics of Respondents (N=100).
Characteristics N
Sex
Male 55
Female 45
Age (yr)
31∼40 37
41∼50 31
≥51 32
Department
Medical oncology 53
Family medicine 30
Anesthesiology 5
Internal medicine, other 3
Surgery 3
Radiation oncology 2
Gynecology 1
Emergency medicine 1
Urology 1
Pediatrics 1
Workplace
General ward 50
Palliative care ward 38
Only outpatient clinic 8
Long-term care facility 4
Years of practice as specialist
≤10 45
11∼20 29
21∼30 21
≥31 5
Average number of cancer patients seen in a month
≤30 36
31∼50 27
51∼100 24
101∼200 6
≥201 7
on drug usage, treatment of BTcP with physician reasoning 
for selecting each drug, important factors in selecting drugs, 
and perceived difficulties in managing breakthrough cancer 
pain. The physicians were also asked how many patients with 
cancer they saw in a month, and whether or not they 
prescribe opioid analgesics for cancer pain. Respondents who 
saw at least 10 cancer patients in a month and answered yes 
to the question of prescribing opioid analgesics for pain were 
included in this survey. To focus on physician practice patterns 
concerning BTcP, this paper presents findings on important 
factors in physician selection of short-acting opioids, drugs of 
choice with reasoning, and perceived difficulties of pain man-
agement among physicians.
3. Statistical analysis
Characteristics of the respondents were summarized as mean 
(SD) or number of subjects (percentage), as appropriate. The 
Mann-Whitney’s U test was used to examine the difference of 
clinical characteristics between general and palliative wards. A 
two-sided P value less than 0.05 was considered as the mini-
mum level of statistical significance. All statistical analyses was 
performed using SAS statistical software, version 9.4 (SAS 
Institute, Cary, NC).
RESULTS
One hundred clinical physicians participated in the 2014 
breakthrough cancer pain survey were analyzed. The mean age 
of participants was 46.1 years, and the majority of partici-
pants were male (55%). The participants belonged to 10 
clinical departments: 53% were from the department of 
medical oncology, 30% were from family medicine, and 17% 
of participants were from other departments. Half of the 
clinicians (50%) worked in the general ward, while 38% of 
clinicians worked in the palliative care ward. In all, 45% of 
clinicians had 10 or fewer years of practice, and the average 
number of years of practices was 14.2 years. One third of 
participants (36%) saw fewer than 30 cancer patients in a 
month, while 27% and 24% of participants saw 31∼50 
patients and 51∼100 patients, respectively (Table 1).
Data regarding the drugs of choice for the management of 
all cancer pain and BTcP are shown in Figure 1. Oxycodone 
was the most commonly prescribed opioid for all cancer pain 
(59%), and immediate-release oxycodone was also frequently 
used for BTcP (65%). Almost all the clinicians that used 
morphine for BTcP preferred parenteral access (27%) rather 
than oral administration (1%) of the drug. The percentage of 
clinicians selecting transmucosal fentanyl to manage BTcP was 
low (3%). Among reasons for selecting immediate-release 
oxycodone to control BTcP, the top two reasons included ease 
of administering the drug (35.4%) and having a lot of 
prescription experience with the drug (27.7%). On the other 
hand, most physicians (81.5%) answered that the reason for 
prescribing parenteral morphine was due to its rapid onset of 
action (Table 2). Findings on physician cognition of charac-
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Figure 2. Influencing factors for prescribing short-acting opioid for 
breakthrough cancer pain.
Figure 1. Drugs of choice for managing all cancer pain and breakthrough cancer pain.
Table 2. Reason for Selecting Preferred Short-Acting Opioid.
Categories
Oral oxycodone 
(N=65)
Parenteral morphine 
(N=27)
N (%) N (%)
Easy to administer 23 (35.4%) 0 (0%)
A lot of prescription experience 18 (27.7%) 1 (3.7%)
Rapid onset of action 14 (21.5%) 22 (81.5%)
Easy to titrate 7 (10.8%) 3 (11.1%)
Strong efficacy 1 (1.5%) 0 (0%)
Less adverse events 1 (1.5%) 0 (0%)
Other comment 1 (1.5%) 1 (3.7%)
Other comment: There is no other medicine to prescribe (N=1).
teristics of each short-acting opioid, including oral oxycodone, 
parenteral morphine, and oral transmucosal fentanyl revealed 
that each drug has different characteristics. Ninety-seven of 
the responding clinicians had experience with prescribing oral 
oxycodone. Collectively, the clinicians had a lot of prescription 
experience (95%) and thought that oral oxycodone is easy to 
administer (84%). However, only 47% of the physicians with 
experience in prescribing oral oxycodone agreed that it has 
rapid onset of action. In the case of parenteral morphine, 98% 
and 95% of 94 clinicians characterized it as having rapid 
onset of action and strong efficacy, respectively. Similar to 
their experience with oral oxycodone, most of the physicians 
had sufficient experience in prescribing parenteral morphine 
(96%). Only 34% of 80 physicians had a lot of experience in 
prescribing oral transmucosal fentanyl, despite 70% and 78% 
characterizing the drug as fast acting and easy to administer, 
respectively.
Influencing factors on the prescription of short-acting opioids 
for BTcP are shown in Figure 2. Rapid onset of action is the 
most important influencing factor in the selection of rescue 
medications by physicians (mean score=4.7). Among the top 
three factors, the remaining two factors are ease of adminis-
tering and strong efficacy of the medications. In the section 
on difficulties in managing BTcP, the majority of clinicians 
(66%) answered that pain is not well controlled for patients, 
despite the use of rescue medications. In contrast, the eco-
nomic burden of high prices for medications was not consi-
dered as a difficulty (Table 3).
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Table 3. Difficulties in Managing Breakthrough Cancer Pain (N=100).
Categories N
Pain is not well controlled with rescue medications. 66
Worries about adverse effects such as respiratory 
depression and delirium.
11
There are not proper opioids for breakthrough pain. 10
High prices of short-acting opioids are burdensome. 7
Other comments 6
Other comments: There is no difficulty in managing breakthrough 
cancer pain (N=2), It is difficult to manage breakthrough cancer 
pain with medications that have short durations of efficacy (N=1), 
Patients do not want to take short-acting opioids, despite education 
about their usefulness (N=1), It is difficult to rapidly administer 
short-acting opioids (N=1), Incident breakthrough pain, including 
moving and urination, is difficult to manage (N=1).
DISCUSSION
The present study demonstrates that there is a gap bet-
ween the needs of physicians in terms of their perceptions 
about the difficulties of managing breakthrough cancer pain 
and their selection of rescue medications. Many physicians 
assert that rapid onset of action is the most important in-
fluencing factor in prescribing short-acting opioids, whereas 
two thirds of physicians have used immediate-release oxyco-
done rather than parenteral morphine and oral transmucosal 
fentanyl in clinical practice. Interestingly, among physicians 
with experience in prescribing oral oxycodone, just one half of 
physicians agreed on its rapid onset of action. In addition, oral 
transmucosal fentanyl, which is known to have faster effects, 
was selected as the rescue medication of choice by only a 
small percentage of respondents. Comparing these findings 
with the findings of other studies, physicians in palliative care 
institutions in Italy commonly prescribe oral morphine to 
manage breakthrough cancer pain, and also use other access 
routes for medications, including subcutaneous and intravenous 
access routes. In contrast, Korean physicians prefer oral oxy-
codone (15). In the case of selecting morphine as a preferred 
rescue medication, most respondent use the parenteral access 
route rather than the oral route. We consider the cause of 
this preference for parenteral morphine to be due to dif-
ferences in workplaces. Subgroup analysis according to work-
place demonstrates that usage of parenteral morphine is 
significantly higher in palliative wards (P＜0.001).
In Korea, patients with advanced cancer stay in the hospi-
tal for a mean of 20.2±21.2 days per admission in the 
palliative ward. More than 70% of these patients face death 
in the hospital (17). More specifically, most patients in the 
palliative ward are in the process of dying, which is related to 
a higher prevalence of dysphagia and dry mouth (18,19). We 
assume that these statistics partly explain why physicians in 
palliative wards have little choice but to commonly prescribe 
parenteral morphine. 
Fentanyl is a potent synthetic opioid with highly lipophilic 
characteristics. It is rapidly absorbed via mucosal membranes 
and diffuses across the blood-brain barrier, resulting in the 
rapid onset of effects (20). A variety of researchers have 
suggested that transmucosal fentanyl preparations might be a 
better fit in managing BTcP than oral opioids, because trans-
mucosal fentanyl has characteristics of short duration and high 
potency in addition to rapid pain response (11,21). Never-
theless, few physicians have prescribed transmucosal fentanyl 
in Korea. In a European survey of 1,000 oncologic patients, 
19.1% of participants answered that they had been prescribed 
fentanyl for BTcP (6). Another survey demonstrates that 
42.1% and 16.2% of physicians in 12 European countries 
normally use oral transmucosal fentanyl and intranasal fentanyl, 
respectively (22). In an Italian survey, 21 of 118 physicians at 
dedicated palliative care institutions select fentanyl alone or 
fentanyl with other opioids as their drug of choice for 
controlling BTcP (15). On the other hand, the percentage of 
Canadian patients with BTcP who had been prescribed 
fentanyl was only 2.9% (16). Based on comparison with the 
physician surveys of other countries, transmucosal fentanyl is 
used more frequently in Korea than in Canada, but less 
frequently than in European countries. We assume that 
prescriptions with characteristics that are unsuitable for BTcP 
might be linked to the perceptions of physicians regarding the 
difficulties of managing BTcP, despite the widespread use of 
rescue medications.
There may be several reasons for differences in prescribing 
opioid analgesics in managing BTcP, especially in the case of 
transmucosal fentanyl, which is known for more effective 
analgesic results.
First, the knowledge of a physician impacts resulting pre-
scriptions. A number of studies have demonstrated the associa-
tion between the knowledge of a medical staff and the 
management of cancer pain (23,24). A lot of medical 
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members rely on specific guidelines in clinical practice. Looking 
into current guidelines in Korea, Canada, and Europe, there 
are some differences in protocol among the countries. Euro-
pean guidelines recommend transmucosal fentanyl as an addi-
tional option for managing BTcP, and indeed, as the pre-
ferable option in some cases (25). On the other hand, 
Canadian guidelines do not include any information about 
transmucosal fentanyl (26). This lack of information may be 
due to the fact that fentanyl preparations have only recently 
become available in Canada (27). Korean guidelines for cancer 
pain management were first published in 2004, and are now 
available in the 6th edition, updated in 2015 (28). Even 
though some improvements in cancer pain management have 
been achieved with these updated guidelines, there is still 
insufficient information to properly define and manage BTcP 
using appropriate analgesics (29). In addition, in a Korean 
survey of physician knowledge about cancer pain guidelines, 
more than 40% of physicians answered incorrectly on items 
related to BTcP (23). Accordingly, further updated guidelines 
based on current data about BTcP, together with continuing 
education for physicians, is warranted to improve the manage-
ment of breakthrough pain for cancer patients.
Second, higher costs might impact physician hesitance to 
prescribe newly-developed medication formulations in practice, 
even though a few physicians answered that they felt diffi-
culties to manage breakthrough cancer pain due to high 
prices. Economic restrictions are suggested as a barrier in 
prescribing rapid-acting opioids in previous research (15). In 
fact, the cost of fentanyl preparations is several times higher 
than the cost of traditional opioids in Korea.
Third, some physicians might be reluctant to prescribe 
recently developed formulations due to lack of experiences of 
prescription in clinical practice. Song et al. reported that 
Korean physicians considered the private experience including 
prescription experience as the most important factor among 
several prescription criteria (30). An oral transmucosal fentanyl 
has been available in many countries since the 1990s. How-
ever, buccal fentanyl preparation was first available in 2008 
and other formulation of fentanyl became available in Korea 
in 2014. Thus, there is not enough time to experience 
characteristics of newly developed formulation in clinical 
practice, resulting in gap between discrepancy and practice. 
The use of opioid analgesics is under strict regulation in 
Korea. The difficulties of opioids storage and administration in 
hospital, especially small hospital, also important factor to 
limit physicians’ experience on prescribing opioids analgesics. 
The optimal balance in regulatory policy will ensure effective 
management of cancer pain and protect patients against 
misuse of opioids.
This study has some limitations. First, the participants may 
not be representative of all palliative care physicians. Almost 
all the respondents were medical oncologists and practitioners 
of family medicine. In addition, the number of physicians who 
participated in this study is relatively low. If more physicians 
from other specialties had been included in this study, then 
the results may have been different. Second, all the partici-
pating physicians herein are members of the KSHPC, and 
therefore are highly dedicated to their work. This probably 
overestimates the results relative to the actual practice 
patterns of physicians involved in the pain management of 
cancer patients. Third, there may be discrepancies between the 
responses of participants about what they would do in theory 
and what they actually do in their workplaces on a daily basis 
in dynamic circumstances. Despite these limitations, we believe 
that the present study is the first to assess the gap between 
the needs of cancer patients and the actual patterns of rescue 
medication prescription among palliative physicians in Korea.
In conclusion, our data suggest that there is a difference 
between the needs of physicians in terms of their perceptions 
about the difficulties of managing breakthrough cancer pain in 
patients and the actual patterns of prescription among pallia-
tive physicians in Korea. The responding physicians felt that 
management of BTcP is difficult. This indicates the need for 
further studies on BTcP related barriers in Korea. We suggest 
that additional researches should focus on more physicians 
treating cancer pain to identify a true picture of the physicians’ 
attitude on BTcP. Moreover, updated guidelines, the conti-
nuing education of physicians, and support from government 
are required to meet patient needs and thereby achieve 
optimal treatment of BTcP.
요      약
목적: 돌발성 통증을 적절히 조절하는 것은 암환자에
서 필수적이다. 돌발성 통증을 조절하는 것은 의료진이 
돌발성 통증에 대해 잘 이해하고 적절한 구제 진통제를 
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사용하는 것에 달려있다. 본 연구는 한국 완화의료 전
문의들의 돌발성 통증에 대한 견해와 진료 형태에 대해 
알아보고자 하였다. 
방법: 본 연구는 한국호스피스 완화의료학회에서 시
행된 2014년 돌발성 통증 설문조사를 바탕으로 진행하
였다. 100명의 의사가 온라인 설문조사에 참여하였다. 
총 33개의 자가 기입식 설문 문항 중에서 12개의 항목
이 분석에 사용되었다.
결과: 빠른 작용 발현은 구제 진통제를 선택함에 있
어 가장 중요한 요소였다. 경구 옥시코돈(65%)과 모르
핀 주사제(27%)는 흔히 사용되는 구제진통제였다. 소수
의 의사들(3%)만이 점막 흡수형 펜타닐을 선호하였다. 
빠른 작용 발현 때문에 경구 옥시코돈을 선택한다고 답
변한 의사들은 21.5%였으며, 반면에 빠른 작용 발현 때
문에 모르핀 주사제를 처방한 의사들은 81.5%였다. 전
체 응답자의 약 66%는 돌발성 통증이 구제 진통제로 
잘 조절되지 않는다고 답변했다.
결론: 돌발성 통증 조절에 의료진들은 어려움을 느끼
고 있었고, 의료진들이 구제진통제를 선택함에 있어서 
필요로 하는 중요한 요소와 실제 처방의 형태에는 차이
가 있었다.
중심단어: 돌발성 통증, 완화의료, 마약성 진통제
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